Genetic Studies Offer Hint Of Clinical Benefits-And Risks- of PCSK9 Inhibitors

–Both cardiovascular benefits and increase in diabetes seem likely. There is no more eagerly awaited question in cardiovascular medicine than the clinical role of the PCSK9 inhibitors. The first reports from a series of outcomes trials are not due until next year. But two large genetic studies published this week deliver strong indirect evidence that…

Click here to continue reading…

Prenatal Genetic Test Billing Practices Questioned

–Sequenom billed insurance companies $2,760 but let patients pay only $200? Patients who order an expensive prenatal genetic test from Sequenom are being told that they will not be held responsible for the vast majority of the bill if it is denied by insurance. This policy may appear to benefit patients but may be considered a…

Click here to continue reading…

Saturated Fats Linked To Heart Disease Once Again

–But critics say that observational studies can’t establish causal relationship. A prominent group of nutrition researchers have once again linked saturated fats to increased coronary heart disease. The new paper, published in BMJ, is the third paper in the past year to decry saturated fats. Along with the previous two papers, published in JACC and JAMA Internal…

Click here to continue reading…

Guest Post: Two Nations Separated by 5.3 mm

Editor’s note: This guest post is by Saurabh Jha, MBBS, a radiologist at the University of Pennsylvania. This post will also be published on The Health Care Blog, where Jha is the associate editor. A popular meme is that the US spends more on healthcare than other developed nations but has nothing to show for…

Click here to continue reading…

Mixed Results For ApoA-1 Therapies

–It’s still not time to write the obituary for all HDL therapies. There was good news and bad news for a category of experimental drugs that attempt to mimic the putative beneficial effect of HDL at the American Heart Association meeting in New Orleans. Thirteen years after setting the field on fire with a promising…

Click here to continue reading…

Lunchroom Scandal At The AHA: Day Two Of Buttergate

–After a CardioBrief investigation the American Heart Association changes the lunchroom menu There is no better proof that journalism can change the world– both for the good and the bad– than Buttergate. Yesterday your intrepid reporter exposed the ongoing scandal of Buttergate taking place within the press lunchroom at the American Heart Association meeting in New…

Click here to continue reading…

Is The American Heart Association Trying To Kill Health Reporters?

The answer is no. The AHA is not trying to kill us. But its dietary advice is consistently confusing and occasionally wrong, and health reporters in New Orleans may end up as collateral damage. Just take a look at what’s being served in the press room at the big American Heart Association meeting going on now…

Click here to continue reading…

Statin Nation ‘Census’ Highlights Major Disparities

–Women, minorities treated at significantly lower rates Anyone reading this is almost certainly aware of the enormous importance of statins in the current health scene. But until now they may have had a hard time to bring precise numbers and statistics to this all important story. Now data from a large federal survey confirm that…

Click here to continue reading…

No Cognitive Benefit from Heart Drugs in HOPE-3

–Substudy finds mental function unimproved by BP, cholesterol treatments NEW ORLEANS — A large substudy of the HOPE-3 trial found no benefit relating to cognitive function in patients who took cholesterol or blood pressure-lowering drugs. In recent years cognitive decline and dementia have emerged as a concern equal if not even greater than cardiovascular disease…

Click here to continue reading…

Debate Ensues As USPSTF Finalizes Statin Primary Prevention Guideline

–Broad disagreement about how, when, and if to use statins. The U.S. Preventive Services Task Force (USPSTF) has issued final recommendations regarding the use of statins for primary prevention of cardiovascular disease in adults. The recommendations, first proposed last December, are broadly consistent with the 2013 American College of Cardiology/American Heart Association guidelines. But accompanying the…

Click here to continue reading…

Cardiac Devices Could Become a Big Problem For Califf And The FDA

–Approvals with no strong evidence of efficacy: What could go wrong?  The FDA has a big problem. It likes to approve new drugs and devices. Approvals look good politically and allow the FDA to boast each year about their large number of approvals. But when the FDA approves a drug or device that doesn’t work…

Click here to continue reading…

Early Watchman Experience Reassuring, But Many Questions Remain

In the year and a half after its approval the Watchman left atrial appendage closure device was successfully implanted 95.6% of the time, or more than 3,600 times out of a total of 3,822 consecutive cases. The finding comes from procedural data collected by Boston Scientific and presented at TCT by Vivek Reddy (Mt. Sinai)…

Click here to continue reading…

The Impact Of ABSORB II: Down The Slippery Slope

When it was approved earlier this year in July the Absorb (Abbott) bioresorbable stent provoked a fair amount of discussion about the “slippery slope of noninferiority.” Although the stent met the FDA criteria for approval, the available trial results went in the wrong direction and there was a particularly concerning warning sign of a higher…

Click here to continue reading…

Pfizer Ends Development Of Its PCSK9 Inhibitor

–Immune issues and diminishing efficacy doomed the new drug. Pfizer announced on Tuesday that it was discontinuing development of bococizumab, its cholesterol-lowering PCSK9 inhibitor under development. “The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide…

Click here to continue reading…

Debaters At Interventional Cardiology Meeting Literally Put The Gloves On

The world’s premiere interventional cardiology meeting now features cardiologists wearing boxing shorts and gloves. The Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC kicked off  with a “Saturday Night Fights” theme for its debate session, and the participants– nearly all greying, eminent male interventional cardiologists– adopted the theme whole-heartedly. All lovey-dovey at the start of #TCT2016 fights pic.twitter.com/upGprIcxkQ…

Click here to continue reading…

Impella No Better Than IABP in Cardiogenic Shock

–Underpowered IMPRESS trial shows no mortality benefit A rare randomized trial and a new meta-analysis both failed to find any evidence that Impella mechanical circulatory support devices are any better than intra-aortic balloon pumps (IABPs) for patients with cardiogenic shock. For many years, the intra-aortic balloon pump has been the standard device to increase circulation…

Click here to continue reading…

Universal Child FH Screening Proposed

–Novel strategy would identify both children and adults at high risk for CV events. Doctors in the U.K. are proposing a novel strategy to identify very young children with familial hypercholesterolemia (FH). The strategy would also identify and help prevent events in the parents who also have FH. The new approach begins with a heel-stick…

Click here to continue reading…

Calcium Levels and CV Risk: New Study Finds No Link

–But most agree dietary calcium is preferable to supplements A new review concludes that a high level of calcium intake, whether from food or supplements, is not linked to increased cardiovascular risk, as long as the total calcium intake remains below the tolerable upper level of intake (2,000-2,500 mg/day). The systematic review, published in Annals…

Click here to continue reading…

Eliquis Nipping At The Heels of NOAC Market Leader Xarelto

–But the overall market for the new oral anticoagulants continues to expand. The new oral anticoagulant (NOAC) market is growing larger and is becoming increasingly competitive. The latest market data shows that apixaban (Eliquis, Pfizer and BristolMyers Squibb) is challenging the established leader in the field, rivaroxaban (Xarelto, Johnson & Johnson). According to recent data…

Click here to continue reading…

Novel Cholesterol Drugs Move Forward In Clinical Trials

–New information about upcoming cholesterol drugs from the Medicines Company and Esperion Recently the makers of two novel cholesterol-lowering drugs in development provided important updates on their progress. On Tuesday, the Medicines Company announced positive top-line results for a trial of its unusual PCSK9 synthesis inhibitor scheduled to be presented in November. Last week Esperion…

Click here to continue reading…

Calcium Supplements Linked To Increased Cardiovascular Risk

–But the observational study suggested an overall benefit for dietary calcium. A new observational study finds that calcium supplements may increase cardiovascular risk. By contrast, dietary calcium was linked to a protective effect. Many people– in particular, older women– take calcium supplements to prevent or treat osteoporosis, though the supporting evidence for this use is…

Click here to continue reading…

FDA Reaffirms Safety And Efficacy Of Rivaroxaban

–FDA says no changes needed to the rivaroxaban label. Following a year of controversy and uncertainty relating to the anticoagulant drug rivaroxaban (Xarelto, Johnson & Johnson), the FDA has reaffirmed the drug’s safety and efficacy. Rivaroxaban is approved for stroke reduction in patients with atrial fibrillation. The indication is based on results of the ROCKET-AF…

Click here to continue reading…

No, $75 Million Won’t Cure Heart Disease Or Reinvent Science

–Silicon Valley hype and hubris come to cardiology. We may be close to peak hype and hubris in cardiology. This week some of the smartest people on the planet said that $75 million can help find new ways to prevent heart disease AND, as if that’s not enough, completely reinvent the way we do science….

Click here to continue reading…

LDL-Lowering Genetic Variants Linked to Diabetes Risk

–What can genetics tell us about diabetes incidence with cholesterol drugs? Editor’s note: The following guest post was contributed by Marilyn Mann, a well-known advocate for patients with familial hypercholesterolemia and a patient advisor to Circulation: Cardiovascular Quality and Outcomes. In a study published in the Journal of the American Medical Association, several LDL-lowering genetic…

Click here to continue reading…

Trump’s Risk For A Cardiac Event Is Seven Times Hilary Clinton’s Risk

Editor’s note: The following guest post is reprinted with permission from Dr. Anthony Pearson, a cardiologist who is the medical director of the Echocardiography Laboratory and Anticoagulation Clinic at St. Lukes Hospital, Chesterfield, Missouri. Dr. Pearson writes The Skeptical Cardiologist blog, where this post originally appeared. Donald Trump recently appeared on the Dr. Oz show and handed a letter to the…

Click here to continue reading…